Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Dermatology Reports
Published in: Current Dermatology Reports 4/2019

01-12-2019 | Cutaneous Paraneoplastic Syndromes | Hospital-Based Dermatology (L Guggina and A Zhou)

Paraneoplastic Syndromes for the Inpatient Dermatologist

Authors: Megan Wetzel, Cindy E. Owen, Jeffrey P. Callen

Published in: Current Dermatology Reports | Issue 4/2019

Login to get access

Abstract

Purpose of Review

There are a variety of distinct clinical presentations of skin diseases associated with an internal malignancy. Herein, we review some of the cutaneous manifestations of paraneoplastic syndromes and dermatoses that may be evaluated in the inpatient setting. Descriptions of clinical findings, associated systemic signs and symptoms, and diagnostic work-up are presented.

Recent Findings

Paraneoplastic syndromes are very rare. Isolated case reports with subsequent pooled literature reviews make up the majority of recent published literature.

Summary

The association between certain skin conditions and malignancies is well established, making them important signs or harbingers of internal disease. Recognizing these paraneoplastic dermatoses during inpatient consultations can result in timely discovery of malignancy.
Literature
1.
Bolognia JL, Brewer YP, Cooper DL. Bazex syndrome (acrokeratosis paraneoplastica). An analytic review. Medicine (Baltimore). 1991;70(4):269–80.
2.
Räßler F, Goetze S, Elsner P. Acrokeratosis paraneoplastica (Bazex syndrome) - a systematic review on risk factors, diagnosis, prognosis and management. J Eur Acad Dermatol Venereol. 2017;31(7):1119–36.PubMed
3.
John AM, Schwartz RA. Glucagonoma syndrome: a review and update on treatment. J Eur Acad Dermatol Venereol. 2016;30(12):2016–22.PubMed
4.
Stacpoole PW. The glucagonoma syndrome: clinical features, diagnosis, and treatment. Endocr Rev. 1981;2:347–61.PubMed
5.
Eldor R, Glaser B, Fraenkel M, Doviner V, Salmon A, Gross DJ. Glucagonoma and the glucagonoma syndrome: a cumulative experience with an elusive endocrine tumor. Clin Endocrinol. 2011;74(5):593–8.
6.
Wermers RA, Fatourechi V, Wynne AG, Kvols LK, Lloyd RV. The glucagonoma syndrome: clinical and pathologic features in 21 patients. Medicine (Baltimore). 1996;75(2):53–63.
7.
Tremblay C, Marcil I. Necrolytic migratory erythema: a forgotten paraneoplastic condition. J Cutan Med Surg. 2017;21(6):559–61.PubMed
8.
Leibowitz MR, Weiss R, Smith EH. Pityriasis rotunda. A cutaneous sign of malignant disease in two patients. Arch Dermatol. 1983;119(7):607–9.PubMed
9.
Finch JJ, Olson CL. Hyperpigmented patches on the trunk of a Nigerian woman. Pityriasis rotunda (PR). Arch Dermatol. 2008;144(11):1509–14.PubMed
10.
Grimalt R, Gelmetti C, Brusasco A, Tadini G, Caputo R. Pityriasis rotunda: report of a familial occurrence and review of the literature. J Am Acad Dermatol. 1994;31(5 Pt 2):866–71.PubMed
11.
van Heerden T, Webb MJ, Barrett CL. Pityriasis rotunda as an incidental paraneoplastic finding in two patients with multiple myeloma. Clin Exp Dermatol. 2014;39(6):734–7.PubMed
12.
Berkowitz I, Hodkinson HJ, Kew MC, DiBisceglie AM. Pityriasis rotunda as a cutaneous marker of hepatocellular carcinoma: a comparison with its prevalence in other diseases. Br J Dermatol. 1989;120(4):545–9.PubMed
13.
Airio A, Pukkala E, Isomaki H. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol. 1995;22(7):1300–3.PubMed
14.
• Fang Y, Wu Y, Kuo CF, Luo SF, Yu KH. Malignancy in dermatomyositis and polymyositis: analysis of 192 patients. Clin Rheumatol. 2016;35(8):1977–84. Provides updated prevalence data and predictive risk factors for malignancy in patients with dermatomyositis. PubMed
15.
Hoesly PM, Sluzevich JC, Jambusaria-Pahlajani A, Lesser ER, Heckman MG, Abril A. Association of antinuclear antibody status with clinical features and malignancy risk in adult-onset dermatomyositis. J Am Acad Dermatol. 2019;80(5):1364–80.PubMed
16.
Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum. 2013;65(11):2954–62.PubMedPubMedCentral
17.
Ting HC, Foo MH, Wang F. Acquired cutis laxa and multiple myeloma. Br J Dermatol. 1984;110(3):363–7.PubMed
18.
New HD, Callen JP. Generalized acquired cutis laxa associated with multiple myeloma with biphenotypic IgG lamda and IgA kappa gammopathy following treatment of a nodal plasmacytoma. Arch Dermatol. 2011;147(3):323–8.PubMed
19.
Silveria L, Torres I, Salvino MA, Follador I, Bittencourt AL. Acquired cutis laxa with an interstitial granulomatous reaction associated with IgG lambda monoclonal gammopathy. Am J Dermatopathol. 2013;35(4):e67–71.PubMed
20.
Appiah YE, Onumah N, Wu H, Elenitsas R, James W. Multiple myeloma-associated amyloidosis and acral localized acquired cutis laxa. J Am Acad Dermatol. 2008;58(2 Suppl):S32–3.PubMed
21.
O’Malley JT, D’Agati VD, Sherman WH, Grossman ME. Acquired cutis laxa associated with heavy chain deposition disease involving dermal elastic fibers. J Am Acad Dermatol. 2014;150(11):1192–6.
22.
Chavarot N, Battistella M, Vignon M, Baron M, Girerd S, Jachiet M, et al. Cutis laxa for diagnosis of γ1-heavy-chain deposition disease: report of four cases. J Dermatol. 2018;45(10):1211–5.PubMed
23.
Nguyen VT, Ndoye A, Bassler KD, Shultz LD, Shields MC, Ruben BS, et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus. Arch Dermatol. 2001;137(2):193–206.PubMed
24.
Ouedraogo E, Gottlieb J, de Masson A, Lepelletier C, Jachiet M, Salle de Chou C, et al. Risk factors for death and survival in paraneoplastic pemphigus associated with hematologic malignancies in adults. J Am Acad Dermatol. 2019;80(6):1544–9.PubMed
25.
Kartan S, Shi VY, Clark AK, Chan LS. Paraneoplastic pemphigus and autoimmune blistering diseases associated with neoplasm: characteristics, diagnosis, associated neoplasms, proposed pathogenesis, treatment. Am J Clin Dermatol. 2017;18(1):105–26.PubMed
26.
• Kwatra SG, Boozalis E, Pasieka H, Anhalt GJ. Decreased recognition of paraneoplastic pemphigus in patients previously treated with anti-CD 20 monoclonal antibodies. Br J Dermatol. 2019;180(5):1238–9. Use of rituximab may affect the clinical presentation as well as laboratory findings and subsequent detection of paraneoplastic pemphigus. PubMed
27.
Ohzono A, Sogame R, Li X, Teye K, Tsuchisaka A, Numata S, et al. Clinical and immunological findings in 104 cases of paraneoplastic pemphigus. Br J Dermatol. 2015;173(6):1447–52.PubMed
28.
Huang Y, Li J, Zhu X. Detection of anti-envoplakin and anti-periplakin autoantibodies by ELISA in patients with paraneoplastic pemphigus. Arch Dermatol Res. 2009;301(10):703–9.PubMed
29.
Leger S, Picard D, Ingen-Housz-Oro S, Arnault JP, Aubin F, Carsuzaa F, et al. Prognostic factors of paraneoplastic pemphigus. Arch Dermatol. 2012;148(10):1165–72.PubMed
30.
Egan CA, Lazarova Z, Darling TN, Yee C, Cote T, Yancey KB. Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet. 2001;357(9271):1850–1.PubMed
31.
Egan CA, Lazarova Z, Darling TN, Yee C, Yancey KB. Anti-epiligrin cicatricial pemphigoid: clinical findings, immunopathogenesis, and significant associations. Medicine (Baltimore). 2003;82(3):177–86.
32.
Gerorgoudis P, Sabatino F, Szentmary N, Palioura S, Fodor E, Hamada S, et al. Ocular mucous membrane pemphigoid: current state of pathophysiology, diagnostics and treatment. Opthalmol Ther. 2019;8(1):5–17.
33.
Chen CT, Hu HY, Chang YT, Li CP, Wu CY. Cancer is not a risk factor for bullous pemphigoid: 10-year population-based cohort study. Br J Dermatol. 2019;180(3):553–8.PubMed
34.
Atzmony L, Mimouni I, Reiter O, Leshem YA, Taha O, Gdalevich M, et al. Association of bullous pemphigoid with malignancy: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(4):691–9.PubMed
35.
Rochet NM, Chavan RN, Cappel MA, Wada DA, Gibson LE. Sweet syndrome: clinical presentation, associations, and response to treatment in 77 patients. J Am Acad Dermatol. 2013;69(4):557–64.PubMed
36.
Heath MS, Ortega-Loayza AG. Insights into the pathogenesis of Sweet’s syndrome. Front Immunol. 2019;10(414):1–22.
37.
• Nelson CA, Noe MH, McMahon CM, Gowda A, Wu B, Aschyan H, et al. Sweet syndrome in patients with and without malignancy: a retrospective analysis of 83 patients from a tertiary academic referral center. J Am Acad Dermatol. 2018;78(2):303–9.e4. Large retrospective analysis which identified several clinicopathologic factors found in malignancy associated Sweet syndrome. PubMed
38.
• Alegria-Landa V, Rodriquez-Pinilla SM, Santos-Briz A, Rodriguez-Peralto JL, Alegre V, Cerroni L, et al. Clinicopathologic, immunohistochemical, and molecular features of histiocytoid Sweet syndrome. J Am Acad Dermatol. 2017;153(7):651–9. Retrospective case series which demonstrated dermal infiltrate of histiocytoid Sweet syndrome is of immature cells of myeloid lineage and should not be mistaken as leukemia cutis.
39.
Ghoufi L, Ortonne N, Ingen-Housz-Oro S, et al. Histiocytoid sweet syndrome is more frequently associated with myelodysplastic syndromes than the classical neutrophilic variant: a comparative series of 62 patients. Medicine (Baltimore). 2016;95(15):e3033.
40.
Kulasekararaj AG, Kordasti S, Basu T, Salisbury JR, Mufti GJ, du Vivier AW. Chronic relapsing remitting sweet syndrome—a harbinger of myelodysplastic syndrome. Br J Haematol. 2015;170(5):649–56.PubMed
41.
Vignon-Pennamen MD, Juillard C, Rybojad M, et al. Chronic recurrent lymphocytic sweet syndrome as a predictive marker of myelodysplasia: a report of 9 cases. Arch Dermatol. 2006;142(9):1170–6.PubMed
42.
Osio A, Battistella M, Feugeas JP, Cuccuini W, Noguera ME, Petrella T, et al. Myelodysplasia cutis versus leukemia cutis. J Invest Dermatol. 2015;135(9):2321–4.PubMed
43.
Ashchyan HJ, Butler DC, Nelson CA, Noe MH, Tsiaras WG, Lockwood SJ, et al. The association of age with clinical presentation and comorbidities of pyoderma gangrenosum. JAMA Dermatol. 2018;154(4):409–13.PubMedPubMedCentral
44.
Binus AM, Qureshi AA, Li VW, Winterfield LS. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol. 2011;165(6):1244–50.PubMed
45.
Braswell SF, Kostopoulos TC, Ortega-Loayza AG. Pathophysiology of pyoderma gangrenosum (PG): an updated review. J Am Acad Dermatol. 2015;73(4):691–8.PubMed
46.
Al Ghazal P, Herberger K, Schaller J, Strolin A, Hoff NP, Goerge T, et al. Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients. Orphanet J Rare Dis. 2013;8:136.PubMedPubMedCentral
47.
Bennett ML, Jackson JM, Jorizzo JL, Fleischer AB Jr, White WL, Callen JP. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore). 2000;79(1):37–46.
48.
Sigurdsson V, Toonstra J, Hazemans-Boer M, van Vloten WA. Erythroderma. A clinical and follow-up study of 102 patients, with special emphasis on survival. J Am Acad Dermatol. 1996;35(1):53–7.PubMed
49.
Tan GFL, Kong YL, Tan ASL, Tey HL, Uk M. Causes and features of erythroderma. Ann Acad Med Singap. 2014;43(8):391–4.PubMed
50.
Cuellar-Barboza A, Ocampo-Candiani J, Herz-Ruelas ME. A practical approach to the diagnosis and treatment of adult erythroderma. Actas Dermosifiliogr. 2018;109(9):777–90.PubMed
51.
Khaled A, Sellami A, Fazaa B, Kharfi M, Zeglaoui F, Kamoun MR. Acquired erythroderma in adults: a clinical and prognostic study. J Eur Acad Dermatology Venereol. 2010;24(7):781–8.
52.
Boyd AS, Neldner KH, Menter A. Erythema gyratum repens: a paraneoplastic eruption. J Am Acad Dermatol. 1992;26(5 Pt 1):757–62.PubMed
53.
Eubanks LE, McBurney E, Reed R. Erythema gyratum repens. Am J Med Sci. 2001;321(5):302–5.PubMed
54.
Raut CP, Kulke MH, Glickman JN, Swanson RS, Ashley SW. Carcinoid tumors. Curr Probl Surg. 2006;43:383–450.PubMed
55.
Bell HK, Poston GJ, Vora J, Wilson NJE. Cutaneous manifestations of the malignant carcinoid syndrome. Br J Dermatol. 2005;152(1):71–5.PubMed
56.
Sadeghian A, Rouhana H, Oswald-Stumpf B, Boh E. Etiologies and management of cutaneous flushing. J Am Acad Dermatol. 2017;77(3):405–14.PubMed
57.
Kanakis G, Kaltsas G. Biochemical markers for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Best Pract Res Clin Gastroenterol. 2012;26:791–802.PubMed
58.
Selmi C, Greenspan A, Huntley A, Gershwin ME. Multicentric reticulohistiocytosis: a critical review. Curr Rheumatol Rep. 2015;17(6):511.PubMed
59.
Benucci M, Sulla A, Manfredi M. Cardiac engagement in multicentric reticulohistiocytosis: report of a case with fatal outcome and literature review. Intern Emerg Med. 2008;3(2):165–8.PubMed
60.
West KL, Spom T, Puri PK. Multicentric reticulohistiocytosis: a unique case with pulmonary fibrosis. Arch Dermatol. 2012;148(2):228–32.PubMed
61.
Agha A, Bateman H, Sterrett A, Valeriano-Marcet J. Myelodysplasia and malignancy-associated vasculitis. Curr Rheumatol Rep. 2012;14(6):526–31.PubMed
62.
Loricera J, Calvo-Rio V, Ortiz-Sanjuan F, Gonzalez-Lopez MA, Ferenandez-Liaca H, Rueda-Gotor J, et al. The spectrum of paraneoplastic cutaneous vasculitis in a defined population: incidence and clinical features. Medicine (Baltimore). 2013;92(6):331–43.
63.
Fain O, Hamidou M, Cacoub P, et al. Vasculitides associated with malignancies: analysis of 60 patients. Arthritis Rheum. 2007;57(8):1473–80.PubMed
64.
Solans-Laque R, Bosch-Gil JA, Perez-Bocanegra C, Selva-O’Callaghan A, Simeon-Aznar CP, Vilardell-Tarres M. Paraneoplastic vasculitis in patients with solid tumors: report of 15 cases. J Rheumatol. 2008;35(2):294–304.PubMed
65.
Podjasek JO, Wetter DA, Pittelkow MR, Wada DA. Cutaneous small-vessel vasculitis associated with solid organ malignancies: the Mayo Clinic experience, 1996 to 2009. J Am Acad Dermatol. 2012;66:e55–65.PubMed
66.
Terzolo M, Reimondo G, Ali A, Bovio S, Daffara F, Paccotti P, et al. Ectopic ACTH syndrome: molecular bases and clinical heterogeneity. Ann Oncol. 2001;12(Suppl 2):S83–7.PubMed
67.
Doi M, Sugiyama T, Izumiyama H, Yoshimoto T, Hirata Y. Clinical features and management of ectopic ACTH syndrome at a single institute in Japan. Endocr J. 2010;57(12):1061–9.PubMed
68.
Sebaratnam DF, Venugopal SS, Frew JW, McMillan JR, Finkelstein ER, Martin LK, et al. Diffuse melanosis cutis: a systematic review of the literature. J Am Acad Dermatol. 2013;68(3):482–8.PubMed
69.
Eide J. Pathogenesis of generalized melanosis with melanuria and melanoptysis secondary to malignant melanoma. Histopathology. 1981;5(3):285–94.PubMed
70.
Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol. 2001;44(2):273–81.PubMed
71.
Rongioletti F, Merlo G, Cinotti E, et al. Scleromyxedema: a multicenter study of & characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol. 2013;69(1):66–72.PubMed
72.
• Rongioletti F, Merlo G, Carli C, Cribier B, Metze D, Calonje E, et al. Histopathologic characteristics of scleromyxedema: a study of a series of 34 cases. J Am Acad Dermatol. 2016;74(6):1194–200. Large case series which demonstrated a subset of patients with scleromyxedema may not have classic histologic features of scleromyxedema and instead have interstitial granuloma annulare-like findings. PubMed
73.
Fleming KE, Virmani D, Sutton E, Langley R, Corbin J, Pasternak S, et al. Scleromyxedema and the dermato-neuro syndrome: case report and review of the literature. J Cutan Pathol. 2012;39(5):508–17.PubMed
74.
Gonzalez J, Palangio M, Schwartz J, Klainer AS, Bisaccia E. Scleromyxedema with dermato-neuro syndrome. J Am Acad Dermatol. 2000;42(5pt2):927–8.PubMed
75.
Mehregan DA, Winkelmann RK. Necrobiotic xanthogranuloma. Arch Dermatol. 1992;128(1):94–100.PubMed
76.
Higgins LS, Go RS, Dingli D, Kumar SK, Rajkumar SV, Dispenzieri A, et al. Clinical features and treatment outcomes of patients with necrobiotic xanthogranuloma associated with monoclonal gammopathies. Clin Lymphoma Myeloma Leuk. 2016;16(8):447–52.PubMed
77.
Hilal T, DiCaudo DJ, Connolly SM, Reeder CB. Necrobiotic xanthogranuloma: a 30-year single-center experience. Ann Hematol. 2018;97(8):1471–9.PubMed
78.
Szalat R, Arnulf B, Karlin L, Rybojad M, Asli B, Malphettes M, et al. Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy. Blood. 2011;118(14):3777–84.PubMed
79.
Adam Z, Zahradova L, Krejci M, Pour L, Koukalova R, Rehak Z. Diffuse plane normolipemic xanthomatosis and necrobiotic xanthogranuloma associated with monoclonal gammopathy—determining the disease stage with PET-CT and treatment experience. Two case studies and literature review. Vnitr Lek. 2010;56:1158–68.PubMed
80.
Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387(10038):2641–54.PubMed
81.
Merlini G. CyBorD: stellar response rates in AL amyloidosis. Blood. 2012;119(19):4343–5.PubMed
82.
Dispenzieri A, Gertz MA, Kyle RA, Lacy MG, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751–7.PubMed
83.
Lecadet A, Bachmeyer C, Buob, Cez A, Georgin-Lavialle S. Minor salivary gland biopsy is more effective than normal appearing skin biopsy for amyloid detection in systemic amyloidosis: a prospective monocentric study. Eur J Intern Med. 2018;57:e20–1.PubMed
84.
Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem. 2009;55(3):499–504.PubMed
85.
Lipsker D. Monoclonal gammopathy of cutaneous significance: review of a relevant concept. J Eur Acad Dermatol Venereol. 2017;31(1):45–52.PubMed
86.
Dispenzieri A. POEMS syndrome: 2017 update on diagnosis, risk stratification, and management. Am J Hematol. 2017;92(8):814–29.PubMed
87.
Bachmeyer C. Acquired facial atrophy: a neglected clinical sign of POEMS syndrome. Am J Hematol. 2012;87(1):131.PubMed
88.
Lee FY, Chiu HC. POEMS syndrome with calciphylaxis: a case report. Acta Derm Venereol. 2011;91(1):96–7.PubMed
89.
Roma I, Filotico R, Cea M, et al. Calciphylaxis in a patient with POEMS syndrome without renal failure and/or hyperparathyroidism. A case report. Ann Ital Med Int. 2004;19(4):283–7.PubMed
90.
Misawa S, Sato Y, Katayama K, Hanaoka H, Sawai S, Beppu M, et al. Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: retrospective cohort study. BMJ Open. 2015;5(11):e009157.PubMedPubMedCentral
91.
Palladini G, Merlini G. The elusive pathogenesis of Schnitzler syndrome. Blood. 2018;131(9):944–6.PubMed
92.
Simon A, Asli B, Braun-Falco M, De Koning H, Fermand JP, Grattan C, et al. Schnitzler's syndrome: diagnosis, treatment, and follow-up. Allergy. 2013;68(5):562–8.PubMed
93.
Sokumbi O, Drage LA, Peters MS. Clinical and histopathologic review of Schnitzler syndrome: the Mayo Clinic experience (1972-2011). J Am Acad Dermatol. 2012;67(6):1289–95.PubMed
94.
Gusdorf L, Asli B, Barbarot S, Neel A, Masseau A, Puechal X, et al. Schnitzler syndrome: validation and applicability of diagnostic criteria in real-life patients. Allergy. 2017;72(2):177–82.PubMed
95.
Claes K, Bammens B, Delforge M, Evenepoel P, Kuypers D, Vanrenterghem Y. Another devastating complication of the Schnitzler syndrome: AA amyloidosis. Br J Dermatol. 2008;158(1):182–4.PubMed
Metadata
Title
Paraneoplastic Syndromes for the Inpatient Dermatologist
Authors
Megan Wetzel
Cindy E. Owen
Jeffrey P. Callen
Publication date
01-12-2019
Publisher
Springer US
Published in
Current Dermatology Reports / Issue 4/2019
Electronic ISSN: 2162-4933
DOI
https://doi.org/10.1007/s13671-019-00277-y

Other articles of this Issue 4/2019

Current Dermatology Reports 4/2019 Go to the issue

Photodermatology (B Adler and V DeLeo, Section Editor)

Photoallergic Contact Dermatitis

Hospital-Based Dermatology (L Guggina and A Zhou)

Management of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: a Review and Update

Infectious Disease and Dermatology (K Krishnamurthy and C Beard), Section Editors)

A Review of Botanicals Exhibiting Antifungal Activity Against Malassezia spp. Implicated in Common Skin Conditions

Hospital-Based Dermatology (L Guggina and A Zhou, Section Editors)

Inpatient Management of Mucocutaneous GVHD

Hospital-Based Dermatology (L Guggina and A Zhou, Section Editors)

An Approach to Retiform Purpura for the Inpatient Dermatologist

Wound Care (H Lev-Tov, Section Editor)

Evidence-Based Review of Clinical Applications and Outcomes of Automated Epidermal Grafting